Physician profile
Danuta Kassur
NPI 1861472946
$713.85
in general payments reported to CMS, 2019-2025
14 companies · $18.62 in 2025
The $18.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $225 · 2024: $29.87 · 2025: $18.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.69 | 2019-2020 | |
| Lilly USA, LLC | $129.11 | 2019-2020 | |
| Novo Nordisk INC | $126.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $119.10 | 2019-2020 | |
| Radius Health, INC. | $29.91 | 2020 | |
| Abbvie INC. | $29.87 | 2024 | |
| Optinose US, INC. | $27.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.37 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $22.94 | 2019 | |
| Glaxosmithkline, LLC. | $18.62 | 2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2019 | |
| Shire North American Group INC | $12.16 | 2019 | |
| Merck Sharp & Dohme LLC | $11.39 | 2019 | |
| Amarin Pharma, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danuta Kassur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.